Related by context. All words. (Click for frequent words.) 69 chemoradiotherapy 68 clinically localized prostate 68 external beam radiotherapy 67 metastatic prostate cancer 67 unresectable tumors 67 prostate cancer CRPC 67 metastatic NSCLC 67 metastatic gastric 67 adjuvant radiotherapy 66 advanced unresectable 66 neoadjuvant chemotherapy 66 adjuvant radiation 66 differentiated thyroid 66 neoadjuvant 65 superficial bladder cancer 65 transplantation HCT 65 androgen deprivation 65 EBRT 64 urothelial cancer 64 metastatic RCC 64 concurrent chemoradiation 64 Neoadjuvant 64 anthracycline taxane 64 fallopian tube carcinoma 64 recurrent ovarian cancer 64 radiotherapy RT 64 allogeneic HSCT 64 metastatic colorectal 64 Androgen deprivation therapy 64 metastatic disease 63 recurrent NSCLC 63 tumor recurrence 63 adjuvant therapy 63 preoperative chemotherapy 63 neoadjuvant therapy 63 cystectomy 63 allogeneic stem cell 63 Radical prostatectomy 63 neoadjuvant treatment 63 recurrent metastatic 63 chemoradiation 63 radiation therapy SBRT 63 metastatic castration resistant 63 metastatic bladder 63 metastatic malignant 63 metastatic breast cancer 63 chemotherapy cisplatin 63 liver resection 63 prostate cancer HRPC 63 recurrent glioblastoma multiforme 63 intravesical therapy 62 distant metastases 62 advanced SCCHN 62 Mitomycin C 62 ELACYT 62 androgen ablation 62 metastatic pancreatic 62 metastatic HER2 positive 62 prostate cancer CaP 62 relapsed ovarian cancer 62 malignant pleural mesothelioma 62 curative resection 62 renal tumors 62 radical prostatectomy RP 62 cytoreduction 62 paricalcitol 62 metastatic HER2 negative 62 colorectal cancer liver metastases 62 pancreatic adenocarcinoma 62 hypervascular tumors 62 irinotecan chemotherapy 62 postoperative chemotherapy 62 localized prostate cancer 62 HER2 positive metastatic breast 62 cytoreductive surgery 62 unresectable 61 goserelin 61 radiochemotherapy 61 PCa 61 refractory ovarian cancer 61 invasive aspergillosis 61 locoregional recurrence 61 Hepatocellular Carcinoma HCC 61 Platinol ® cisplatin 61 palliation 61 peritoneal cancer 61 hormone receptor positive 61 Surgical resection 61 radical prostatectomy 61 sorafenib Nexavar 61 autologous transplants 61 estramustine 61 HNSCC 61 hepatic metastases 61 nonmetastatic prostate cancer 61 undergone radical prostatectomy 61 LHRH receptor positive 61 stage IIIb IV 61 hyperplasia BPH 61 colorectal liver metastases 61 cerebral vasospasm 61 BCG refractory 61 Degarelix 60 androgen suppression therapy 60 metastatic renal cell carcinoma 60 cisplatin chemotherapy 60 antitumor effect 60 metastatic GIST 60 alkylating agent 60 Pemetrexed 60 imatinib therapy 60 microsphere therapy 60 bone metastases 60 allogeneic hematopoietic stem cell 60 prostate cancer PCa 60 beam radiotherapy 60 EFAPROXYN 60 debulking surgery 60 stage IIIB 60 gemcitabine chemotherapy 60 ximelagatran 60 induce remission 60 allogeneic bone marrow 60 bevacizumab Avastin 60 liver metastases 60 pediatric malignancies 60 depsipeptide 60 operable breast cancer 60 hormone refractory prostate cancer 60 androgen suppression 60 NMIBC 60 chemotherapeutic regimens 60 adjuvant therapies 60 unresectable liver cancer 60 axillary dissection 60 invasive candidiasis 60 androgen deprivation therapy 60 severe oral mucositis 60 resectable 60 recurrent malignant glioma 60 Proxinium TM 60 Selective Internal 60 metastatic pancreatic cancer 60 relapsed MM 60 Metastatic Prostate Cancer 60 olaparib 60 endoscopic resection 60 metastatic basal cell 60 non squamous NSCLC 60 eribulin mesylate 60 malignant ascites 60 metastatic androgen independent 60 advanced epithelial ovarian 59 FUSILEV enhances 59 urothelial bladder cancer 59 advanced metastatic prostate 59 colorectal adenoma 59 taxane chemotherapy 59 EUS FNA 59 GnRH agonists 59 Hormonal therapy 59 gastrointestinal stromal tumors GIST 59 metastatic castrate resistant 59 Adjuvant chemotherapy 59 curative therapy 59 Shark cartilage 59 pegylated liposomal doxorubicin 59 AVODART 59 lymph node dissection 59 NATRECOR ® 59 prostate cancer mCRPC 59 HER2 positive breast cancer 59 transarterial 59 biochemical recurrence 59 chemoradiation therapy 59 undergoing radical prostatectomy 59 Hydroxyurea 59 metastatic liver 59 AGILECT R 59 recurrent ovarian 59 Vicinium TM 59 hormone LHRH agonist 59 esophagogastric 59 epirubicin 59 TTF Therapy 59 Bezielle 59 CMV disease 59 advanced metastatic renal 59 Belldegrun 59 parathyroidectomy 59 hormonal therapies 59 radical cystectomy 59 epithelial ovarian 59 pelvic malignancies 59 prednisone prednisolone 59 neoplasia 59 aromatase inhibitor therapy 59 mycophenolate mofetil 59 intravenous bisphosphonates 59 castrate resistant prostate cancer 59 TNFerade TM 59 advanced HER2 positive 59 antithrombotic therapy 59 ZACTIMA 59 erlotinib Tarceva ® 59 adjuvant chemotherapy 59 castration resistant prostate cancer 59 resistant ovarian cancer 59 symptomatic BPH 59 YONDELIS 59 postoperative radiotherapy 59 alkylating agents 59 renal transplantation 59 BRCA deficient 59 cediranib 59 pain palliation 59 LHRH agonists 59 non resectable 59 focal cryoablation 59 taxane therapy 59 treat benign prostatic 59 calcineurin inhibitor 59 nonsmall cell lung cancer 59 CYT# potent vascular disrupting 59 advanced adenomas 59 CTAP# Capsules 58 micrometastases 58 locoregional 58 contralateral breast 58 autologous transplant 58 histologically confirmed 58 refractory angina 58 Intravenous immunoglobulin 58 biochemical relapse 58 Adjuvant therapy 58 cytotoxic therapy 58 Tavocept 58 docetaxel Taxotere ® 58 prostate carcinoma 58 MRgFUS 58 transarterial chemoembolization 58 gefitinib Iressa 58 gemcitabine Gemzar 58 intraperitoneal chemotherapy 58 chemo radiotherapy 58 ductal breast cancer 58 radiation chemoradiation 58 relapsing remitting MS RRMS 58 epithelial tumors 58 thromboembolic complications 58 nonalcoholic steatohepatitis NASH 58 docetaxel Taxotere 58 benign prostatic hypertrophy 58 prolongs survival 58 tumor resection 58 papillary renal cell carcinoma 58 orchiectomy 58 flutamide 58 Faslodex 58 minimally symptomatic 58 VFEND 58 stage IIIA 58 benign prostatic hyperplasia enlarged 58 GnRH agonist 58 thromboembolic disease 58 docetaxel chemotherapy 58 symptomatic paroxysmal AF 58 nonmetastatic 58 AA Amyloidosis 58 biliary tract cancer 58 Her2 positive 58 endometrial hyperplasia 58 pelvic lymphadenectomy 58 microwave hyperthermia 58 adenomatous 58 metastatic 58 FIRMAGON 58 metastatic neuroendocrine tumors 58 Stereotactic body 58 Sentinel node biopsy 58 hormone refractory metastatic prostate 58 malignant neoplasms 58 relapsed ALL 58 interferon beta therapy 58 5FU 58 pertuzumab 58 R0 resection 58 Accelerated Partial Breast Irradiation 58 vandetanib 58 velafermin 58 hormonal therapy 58 lymphadenectomy 58 metastatic adenocarcinoma 58 anastrazole 58 Doxil ® 58 metastatic cancers 58 radiofrequency ablation RFA 58 peritoneal carcinomatosis 58 anti angiogenic therapy 58 metastatic hormone refractory 58 prognostic indicator 58 bevacizumab Avastin ® 58 gastrointestinal stromal tumor GIST 58 cardiotoxic 58 metastatic lung cancer 58 Gliadel Wafer 58 interferon ribavirin 58 PSADT 58 Navelbine ® 58 bevacizumab Avastin Genentech 58 riociguat 58 Radiofrequency ablation 58 TACE 58 thoracoscopic lobectomy 58 bone metastasis 58 chemoembolization 58 transplantation HSCT 58 colorectal tumors 58 cytoreductive nephrectomy 58 epithelial ovarian cancer 58 pelvic radiotherapy 57 TKI therapy 57 neoplasia PIN 57 venous thromboembolic events 57 thymic carcinoma 57 beta blocker therapy 57 temsirolimus 57 STRIDE PD 57 PSA nadir 57 cutaneous melanoma 57 lenalidomide Revlimid R 57 breast endometrial 57 radioiodine therapy 57 leukemia AML 57 Ophena TM 57 cervical lesions 57 recurrent GBM 57 skeletal metastases 57 decompensated cirrhosis 57 ALA PDT 57 Sanofi Aventis Taxotere 57 CBLC# 57 Renal Cell Carcinoma RCC 57 postoperative AF 57 invasive lobular carcinoma 57 metastatic tumors 57 TURP 57 Benign Prostatic Hyperplasia BPH 57 autologous hematopoietic stem cell 57 lapatinib Tykerb 57 #.#ng/ml 57 cisplatin gemcitabine 57 GP IIb IIIa inhibitors 57 evaluating tivozanib 57 adjuvant colon cancer 57 relapsed CLL 57 antifungal therapy 57 androgen independent 57 factor Xa inhibitor 57 medically inoperable 57 cinacalcet 57 metastases 57 lupus nephritis 57 trastuzumab Herceptin ® 57 soft tissue sarcomas 57 atypical ductal hyperplasia 57 nephron sparing surgery 57 luteinizing hormone releasing 57 fallopian tube cancers 57 neuroendocrine cancers 57 distant metastasis 57 IV NSCLC 57 HRPC 57 LHRH agonist 57 H. pylori eradication 57 atrial arrhythmias 57 chronic ITP patients 57 metastatic malignant melanoma 57 intra arterial chemotherapy 57 antiplatelet therapy 57 perioperatively 57 myeloablative 57 transurethral resection 57 fluorouracil 57 metastatic cancer 57 postoperative morbidity 57 situ LCIS 57 chemopreventive agent 57 chemotherapeutic agent 57 Metastatic colorectal cancer 57 receptor tyrosine kinase inhibitor 57 endometriosis ovarian cysts 57 tamoxifen Nolvadex ® 57 idarubicin 57 patients undergoing CABG 57 neurologic progression 57 antihypertensive therapy 57 hepatocellular carcinoma 57 liver metastasis 57 renal cell carcinoma 57 prostate tumor 57 colorectal carcinoma 57 hormonal treatments 57 Tibolone 57 stem cell engraftment 57 Mitoxantrone 57 radiotherapeutic 57 BrachySil TM 57 5-fluorouracil/leucovorin 57 deferiprone 57 radiotherapy SBRT 57 Anthracycline 57 node metastases 57 mRCC 57 Gefitinib 57 brain metastases 57 MYLOTARG 57 catheter angiography 57 tamoxifen therapy 57 sorafenib tablets 57 Alessandro Riva 57 EGFR expressing 57 prostatectomy 57 CIMZIA ™ 57 assessing T DM1 57 lobular carcinoma 57 mycophenolate mofetil MMF 57 MGd 57 Oxaliplatin 57 Tarceva TM 57 acadesine 57 cilengitide 57 zoledronic acid 57 cytotoxic chemotherapy 57 cervical carcinoma 57 cervical lymph nodes 57 elective PCI 57 letrozole Femara 57 Halaven 56 chemopreventive 56 Combination therapy 56 autologous transplantation 56 oral leukoplakia 56 leiomyomas 56 cabazitaxel 56 ovarian lung 56 5 Fluorouracil 56 acute GvHD 56 lung resection 56 mutated KRAS gene 56 cetuximab Erbitux 56 Femara letrozole 56 localized renal 56 metastatic lesions 56 symptomatic benign prostatic 56 CALGB # [001] 56 selenium supplementation 56 Fludarabine 56 paclitaxel cisplatin 56 polyp recurrence 56 prostate cancer 56 renal cell carcinomas 56 non resectable metastatic 56 dasatinib Sprycel 56 EGFRIs 56 paclitaxel Taxol R 56 Taxotere docetaxel 56 sipuleucel T 56 prostate adenocarcinoma 56 colorectal cancer CRC 56 DAPT 56 menopausal symptom 56 ASCT 56 hormone deprivation 56 dalteparin 56 micrometastasis 56 thrombotic complications 56 Panzem R NCD 56 chemoresistant 56 chronic thromboembolic pulmonary 56 surgical debulking 56 ErbB2 positive 56 seminoma 56 antiestrogen therapy 56 lung metastases 56 ibandronate 56 keloid scarring 56 hereditary deficiency 56 HER2 amplified 56 refractory acute myeloid 56 variceal bleeding 56 metachronous 56 DU #b 56 postoperative atrial fibrillation 56 sentinel lymph node biopsy 56 paroxysmal AF 56 kidney urologic 56 haematological cancers 56 Aplidin 56 taxane refractory 56 DFMO 56 basal cell carcinoma BCC 56 colon rectal 56 oral rivaroxaban 56 pegfilgrastim 56 immunosuppressive regimens 56 variceal hemorrhage 56 HER2 negative 56 oral deforolimus 56 PROLARIS 56 pancreatic carcinoma 56 epirubicin cyclophosphamide 56 HIPEC 56 Taxotere chemotherapy 56 gastrointestinal stromal tumor 56 uterine fibroid embolization 56 asymptomatic carotid stenosis 56 Tarceva erlotinib 56 secondary hyperparathyroidism 56 neoadjuvant setting 56 HER2 expressing 56 edifoligide 56 refractory prostate cancer 56 metastatic CRPC 56 biliary strictures produced 56 bilateral oophorectomy 56 Xeloda capecitabine 56 zoledronic acid Zometa 56 dasatinib Sprycel ® 56 recurrent glioblastoma 56 histologically proven 56 IV bisphosphonates 56 stereotactic radiotherapy 56 refractory AML 56 poorer prognosis 56 serum PSA 56 symptomatic fibroids 56 thromboembolic events 56 MAGE A3 ASCI 56 refractory colorectal cancer 56 advanced NSCLC 56 vasospasm 56 Adjunctive 56 verteporfin 56 corticosteroid therapy 56 taxane chemotherapy administered 56 conformal radiotherapy 56 undergoing coronary angiography 56 Vandetanib 56 Ceplene/IL-2 56 TNF Tumor Necrosis Factor 56 SHPT 56 T1DM 56 endometrial carcinoma 56 Hodgkin lymphoma HL 56 glycoprotein IIb IIIa inhibitors 56 endocrine therapies 56 Cristofanilli 56 oral clodronate 56 hemodilution 56 gynecologic malignancy 56 thromboprophylaxis 56 Toremifene 56 plasma kallikrein inhibitor 56 Irinotecan 56 thetreatment 56 fulvestrant 56 non metastatic osteosarcoma 56 caspofungin 56 vasomotor symptoms 56 spinal metastases 56 acute gout flares 56 prostate carcinomas 56 efaproxiral 56 lipid lowering therapies 56 metastatic kidney 56 radiation therapy 56 colorectal cancer 56 recurrent myocardial infarction 56 lung metastasis 56 hepatocellular carcinoma HCC 56 everolimus eluting stents 56 heavily pretreated patients 56 untreated metastatic melanoma 56 postoperative mortality 56 preoperative radiotherapy 56 delayed CINV 56 ocular melanoma 56 hormone receptor negative 56 percutaneous cryoablation 56 abiraterone 56 venous thromboembolic disease 56 unresectable locally advanced 56 hypofractionated 56 esophageal carcinoma 56 standard chemotherapy regimen 56 pulmonary hypertension PH 56 dexpramipexole 56 adalimumab Humira 56 paclitaxel Taxol 56 temozolomide 56 TRUS biopsy 56 bladder carcinoma 56 Nexavar sorafenib 56 Dupuytren Disease 56 platelet inhibitor 56 allogeneic transplants 56 advanced hepatocellular carcinoma 56 ABVD 56 Rituxan rituximab 56 imatinib Gleevec 56 overactive bladder OAB 56 vinca alkaloids 56 fibrate drugs 56 colorectal lung 56 inhibitor RG# 56 ductal carcinomas 56 treat enlarged prostates 56 fibrinolysis 56 prostate cancer AIPC 56 elacytarabine 56 allogeneic hematopoietic cell 56 relapsed leukemia 56 deCODE ProstateCancer TM 56 bisphosphonate therapy 56 parathyroid 56 GISTs 56 chemotherapeutic drug 56 heavily pretreated 56 teriflunomide 56 Torisel 56 refractory NSCLC 56 esophagogastric junction 56 imexon 56 breast carcinoma 56 thrombocytopenic 56 sunitinib Sutent 56 prostate TURP 56 hematological disorders 56 therapeutic regimens 56 hepatic fibrosis 56 Cystectomy 56 HER2 positive cancers 56 bendamustine 56 lymphatic mapping 56 randomized multicenter trial 56 Certolizumab pegol 56 Thal Dex 56 CTEPH 56 ixabepilone 56 allograft rejection 56 chemosensitivity 56 para aortic 56 surgical revascularization 56 decompressive surgery 56 systemic corticosteroid 56 precancerous condition 56 ARIMIDEX 55 cancerdefine 55 underwent prostatectomy 55 palliative radiotherapy 55 malignant pheochromocytoma 55 remission induction 55 FSAD 55 paclitaxel carboplatin 55 nodal metastasis 55 antiarrhythmic drugs 55 alvespimycin 55 malignant lymphoma 55 liver fibrosis 55 pulmonary artery banding 55 interventional therapies 55 surgically resectable 55 VALSTAR TM 55 chemotherapy regimens 55 alpha blocker 55 nab paclitaxel 55 HER2 expression 55 metastatic HER 55 metastatic colorectal carcinoma 55 eribulin 55 Sunitinib 55 specific antigen PSA 55 advanced adenoma 55 efalizumab 55 Genasense ® 55 resectable pancreatic cancer 55 castrate resistant 55 Sorafenib 55 ToGA 55 TUMT 55 cutaneous squamous cell carcinoma 55 immunosuppressant drug 55 β blockers 55 CMV infections 55 mixed hyperlipidemia 55 Imatinib 55 blood clot dissolving 55 myeloproliferative disorders 55 lymph node involvement 55 biologic therapy 55 raloxifene Evista 55 strontium ranelate 55 underwent resection 55 SCIg 55 situ CIS 55 ablative therapy 55 NSTE ACS 55 sentinel node biopsy 55 deep venous thromboses 55 mTOR inhibitor 55 neuroendocrine tumors 55 angiogenesis inhibitor 55 relapsing MS 55 unresectable stage 55 percutaneous ablation 55 intravesical 55 EGFR mutation 55 cisplatin resistant 55 cranial radiation 55 grade gliomas 55 revascularization procedures 55 oral ridaforolimus 55 advanced medullary thyroid 55 antiangiogenic therapy 55 pulmonary metastasis 55 uric acid lowering 55 Zoledronic acid 55 gastrointestinal GI cancers 55 paclitaxel poliglumex 55 Amrubicin 55 parathyroid carcinoma 55 ovarian carcinoma 55 noninvasive outpatient 55 Surgical excision 55 basal cell cancers 55 etoposide 55 adriamycin 55 Elocalcitol 55 Cetuximab 55 Natalizumab 55 thalidomide Thalomid 55 breast cancer recurrence 55 adenoma recurrence 55 carotid endarterectomy CEA 55 metastatic ocular 55 precursor lesions 55 infliximab Remicade 55 azacitidine 55 dose melphalan 55 CIN2 + 55 nonmyeloablative 55 Xelox 55 metastatic HRPC 55 chemotherapeutic regimen 55 hormonally responsive 55 abnormal uterine bleeding 55 Candida infection 55 MitraClip device 55 ocular disorders 55 bladder tumors 55 mTOR inhibitors 55 Chronic Heart Failure 55 lung pancreatic 55 standard chemotherapy regimens 55 lymphomas leukemias 55 selective estrogen receptor modulators 55 Gemcitabine 55 colorectal neoplasms 55 exemestane 55 metastatic ovarian cancer 55 acute ischemic stroke 55 multicentric 55 B7 H3 55 chronic periodontitis 55 systemic immunosuppressive drugs 55 optimal dosing 55 hormone refractory 55 gastrointestinal stromal tumors 55 esophagectomy 55 squamous cell lung cancer 55 T1c 55 radiation sensitizer 55 ATACAND 55 RoACTEMRA 55 Cabazitaxel 55 multi kinase inhibitor 55 multiple myeloma MM 55 rt PA 55 AA amyloidosis 55 GnRH analogue 55 eflornithine 55 tumor necrosis 55 adjunct therapy 55 transurethral 55 recurrent venous thromboembolism 55 SIR Spheres 55 lymph node metastases 55 ancrod 55 FOLFOX6 55 HGPIN 55 Pertuzumab 55 esophageal candidiasis 55 undergoing cardiac catheterization 55 exemestane Aromasin 55 lung tumors 55 palifermin 55 intravenous cyclophosphamide 55 Liver transplantation 55 benign prostatic hypertrophy BPH 55 Azacitidine 55 docetaxel 55 cardiovascular morbidity 55 ipsilateral breast 55 F FDG PET 55 Exemestane 55 SNT MC# 55 intracranial stenosis 55 adrenalectomy 55 HER2 positive 55 bladder cancers 55 Cloretazine 55 HuMax EGFr 55 cancer mCRC 55 dexamethasone Decadron 55 Mohs micrographic surgery 55 FDG PET 55 prostate brachytherapy 55 prostate cancers 55 tamsulosin 55 invasive coronary angiography 55 neo adjuvant 55 dose cytarabine 55 postsurgical pain 55 secondary amenorrhea 55 diagnosed multiple myeloma 55 gastrointestinal cancers 55 Advagraf 55 symptomatic uterine fibroids 55 FOLFOX4 55 squamous histology 55 HIV HCV coinfected 55 endocrine therapy 55 medullary thyroid cancer 55 direct thrombin inhibitors 55 KRAS mutations occur 55 grade cervical intraepithelial 55 pancreatic resection 55 SCCHN 55 mitomycin C 55 lymph node metastasis 55 nephrotoxicity 55 malignant lymphomas 55 thromboembolisms 55 telomerase inhibition 55 GOUT 55 Gemzar gemcitabine 55 pancreatic colon 55 antiangiogenic agent 55 reinfarction 55 Circulating tumor cells 55 macrovascular 55 cilostazol 55 cytogenetic responses 55 intestinal polyps 55 chronic hemodialysis 55 KRAS status 55 ER CHOP 55 sacral nerve stimulation 55 Glioblastoma Multiforme 55 Anastrozole 55 allogeneic SCT 55 sustained virological response 55 ductal lavage 55 BoNTA 55 systemic toxicity 55 Afatinib 55 grade glioma 55 polycythemia vera PV 55 EGFR TKI 55 aromatase inhibitors AIs 55 lymphoma CTCL 55 EOquin TM 55 stage IIIB IV 55 intensity modulated radiotherapy 55 anti androgen 55 post thrombotic syndrome 55 salpingo oophorectomy 55 MYDICAR ® 55 sirolimus 55 trials RCTs 55 previously untreated follicular 55 nondiabetic patients 55 pancreatic lung 55 Everolimus 55 nonsquamous 55 mycosis fungoides 55 adjuvant cisplatin 55 Glioblastoma Multiforme GBM 55 sunitinib malate 55 cirrhotic patients 55 abiraterone acetate 55 SERCA2a 55 testicular germ cell 54 axitinib 54 overlapping toxicities 54 relapsing multiple sclerosis 54 metastatic colorectal cancer 54 recurrent colorectal cancer 54 Cisplatin 54 platinum refractory 54 phase IIb clinical 54 endothelin antagonists 54 tumors GIST 54 lymphoid malignancies 54 therapy IMRT 54 acute STEMI 54 Vidaza azacitidine 54 antirheumatic 54 opioid analgesia 54 antiandrogen 54 chlorambucil 54 5 FU leucovorin 54 liver transplant recipients 54 IORT 54 PCNSL 54 Abiraterone 54 perioperative complications 54 IDO inhibitor 54 colon tumors 54 chemotherapeutic agents 54 recurrent epithelial ovarian 54 Cell Lymphoma CTCL 54 pazopanib 54 intra arterial 54 EBUS FNA 54 laparoscopic fundoplication 54 glucocorticoid therapy 54 pulmonary metastases 54 N acetylcysteine 54 ACTEMRA TM 54 gastric cancer 54 transplant ASCT 54 hypercalcemia 54 urinary tract symptoms LUTS 54 hyperphenylalaninemia HPA due 54 donor nephrectomy 54 extracranial 54 endometrial cancers 54 FASLODEX 54 atherothrombotic events 54 urothelial carcinoma 54 thyroid nodules 54 immunomodulatory agents 54 anticancer therapy 54 BRAF inhibitors 54 metastatic CRC 54 Herceptin trastuzumab 54 rituximab Rituxan 54 Coronary Artery Bypass Graft 54 LHRH analogues 54 SERMs 54 Xanafide 54 antiangiogenic 54 NSCLC 54 anastrozole 54 recurrent glioblastoma multiforme GBM 54 pCR 54 mapatumumab 54 neuropathy sparing 54 cetuximab Erbitux R 54 estrogen receptor negative 54 galiximab 54 Gleevec resistant 54 phase IIb study 54 vidofludimus 54 immunomodulatory therapy 54 mucinous 54 intratumoral 54 Sentinel Lymph Node Biopsy 54 antitumor activity 54 OPCAB 54 chlamydial infection 54 Teverelix 54 metastatic renal cell 54 intraductal 54 pancreatectomy 54 Telintra 54 ZOLINZA 54 refractory CLL 54 carotid stenosis 54 Chemoradiation 54 doublet chemotherapy 54 Ixempra 54 indolent lymphomas 54 ACOSOG Z# 54 acute GVHD 54 unfractionated heparin UFH 54 metastatic bone